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Abstract: The incidence of Multiple myeloma (MM) increases with age; two-thirds of 
the patients are older than 65 years. Induction treatment, including new agents such 
as thalidomide, bortezomib, and lenalidomide followed by a conditioning regimen and 
upfront autologous stem cell transplantation (ASCT), has been accepted the standard 
treatment approach for newly diagnosed fit MM patients. We aimed to search the real-
life data, the efficacy and safety of upfront ASCT following induction in patients with 
MM over 60 years old retrospectively. The data of MM patients who were ≥60 years 
old during autologous stem cell transplantation and treated at our center between 2010 
and 2018 retrospectively analyzed. The study results were 63 patients included at the 
age of ≥ 60 years who underwent upfront ASCT. Median PFS was 15.5±2.6 months, 
and the median overall survival (OS) was 28.15±5 months. According to age groups, 
median PFS was 12±2.3 months in the 60-64 age group, 18.4±6 months in the 65-69 
age group, and 26±15 months in the ≥70 age group. Median OS was 26.5±6.1 months 
in the 60-64 age group, 39.66±8.9 months in the 65-69 age group, and 18 months in 
the ≥70 age group. A significant relationship between the quantity of infused CD34+ 
stem cells and PFS and OS (p:0.05 and p<0.00, respectively). Our study indicated that 
a high dose (200 mg/m2 ) melphalan could safely be used in the physically fit patients 
at the ages of 60-69, and a reduced amount (140 mg/m2 ) would be the appropriate 
dose for the patients over 70. The quantity of infused CD34+ stem cells affect elderly 
MM patients; mobilization dynamics are also important factors for elderly myeloma. 
Age itself should not consider a barrier to ASCT, and a comprehensive geriatric 
evaluation should perform on elderly patients. 




Multiple myeloma (MM) is a plasma cell malignancy in which clonal plasma cells 
produce monoclonal immunoglobulins. MM patients usually present with skeletal 
destruction with osteolytic lesions and pathologic fractures, hypercalcemia, renal 
insufficiency, and anemia. MM accounts for 10% of hematological neoplasms 
(Rajkumar SV,2018). Incidence of MM increases with age; the median age at 
diagnosis is 70 years, two-thirds of the patients are older than 65 years (Palumbo A, 
2012; Harousseau JL, 2008; Mina R, 2019). 
Induction treatment including novel agents such as proteosome inhibitors 
(bortezomib) or immunomodulators (thalidomide, lenalidomide) followed by upfront 
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autologous stem cell transplantation (ASCT) has been accepted as the standard 
treatment approach for newly diagnosed fit MM patients (Palumbo A, 2012; 
Harousseau JL, 2008; Mina R, 2019). Chronological age alone does not constitute an 
obstacle for the conditioning regimen of hematopoietic stem cell transplantation 
(Klepin HD, 2006; Cavo M, 2011; Manupuram S, 2018). 
Autologous stem cell transplantation may also consider for physically fit elderly 
patients with no comorbidities; however, MM patients over 70 years old are not seen 
appropriate for high dose conditioning due to toxicities, impairments of organ 
functions, decreased drug metabolisms, and increased risk of frailty by the advanced 
age (Palumbo A, 2012; Harousseau JL, 2008; Klepin HD, 2006; Cavo M, 2011; Mina 
R, 2019) Hence, most of the randomized clinical trials comparing ASCT and 
conventional chemotherapy have excluded elderly patients (Cavo M, 2011; Wildes 
TM, 2014; McCarthy PL, 2013; Mina R, 2019). In the absence of randomized studies, 
the safety, efficacy, and toxicities of ASCT in MM patients aged ≥65 years are still 
uncertain (Mizuno S, 2019). 
 Over the past two decades, the rate of adults older than 70 years undergoing 
ASCT increased more than five-fold, from less than 1% to nearly 5% (McCarthy PL, 
2013; Manupuram S, 2018). Several cohort studies compared the survival and 
response rates in patients younger vs. elderly for ASCT. The studies showed that 
lower doses of melphalan (100-140 mg /m2) would be appropriate for MM patients up 
to 75 years-old for ASCT conditioning (Facon T, 2007; Palumbo A, 1999; Badros A, 
2001). Moreover, in another phase III trial, melphalan and prednisolone plus 
thalidomide (MPT) were superior to conditioning with melphalan (100 mg/m2) in 
patients between 65 and 75 years of age (Facon T, 2007). A careful assessment 
should identify eligible elderly patients for ASCT, regardless of their chronological age 
(Klepin HD, 2006; Mizuno S, 2019). In the era of the increasing use of upfront ASCT 
after induction therapy with novel agents in MM elderly patients, we aimed to search 
the real-life data, the efficacy and safety of upfront ASCT in MM patients over 60 years 
old our center retrospectively.  
 
MATERIALS AND METHOD 
Data of MM patients older than 60 years old who underwent transplantation at 
Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital 
between 2010 and 2018 were retrospectively analyzed. The local ethics committee 
approved the study of our center (2019-09/399). All patients received a novel agent of 
proteasome inhibitors, bortezomib, with cyclophosphamide and dexamethasone 
named as ‘VCD’ for induction therapy. Patients are classified into three different age 
groups (60-64, 65-69, and ≥70 years). Patients that <70 years old administered 200 
mg/m2 melphalan for conditioning of ASCT, whereas patients that 70 years and above 
received 140 mg/m2 melphalan. The melphalan dose was reduced to 140 mg/m2 for 
patients with serum creatinine levels of ≥2.0 mg/dL before conditioning. Patients 
mobilized with 10 μg/kg subcutaneous granulocyte-colony stimulating factor (G-CSF) 
in 2 divided doses (2×5 mcg/kg). Patients who a mobilization failure with G-CSF alone 
mobilize with high dose cyclophosphamide (4.000 mg/m2) plus G-CSF. In the third 
step, the patient could not mobilize with a high dose of cyclophosphamide (4.000 mg 
/ m2) plus G-CSF; mobilization performed using plerixafor plus G-CSF. Peripheric 
blood-derived stem cells with a continuous blood separator flow (Fresenius Kabi, 
COM.TEC, Germany). A total volume of 150 to 400 mL/kg blood process for each 
apheresis at a flow rate of 50 to 60 mL/min.  The tandem transplant patients in the 
study; described the second ASCT 6 months after the first ASCT without any 
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progression or relapse. Durie Salmon (DS) and the International Staging System (ISS) 
were used for risk classification (Greipp PR, 2005).  
During ASCT, neutropenia, defined as absolute neutrophil count (ANC), was < 
500/mm3, and thrombocytopenia as platelet counts < 20000/mm3. The engraftment 
definition for neutrophil define as the first day when the absolute neutrophil count 
(ANC) was >500/mm3 or 1000/mm3 for three consecutive days, and thrombocyte 
engraftment describes as the first day when thrombocyte count was >20000/mm3 for 
three straight days without transfusion. All patients received weight adapted G-CSF 
before the neutrophil engraftment. The treatment response evaluates the criteria of 
the International Multiple Myeloma Working Group (IMWG) (Durie BG, 2006). 
Complete response (CR) define as negative immunofixation in serum and urine, lack 
of plasmacytomas, and less than 5% plasma cells in the bone marrow. A reduction in 
serum M protein of ≥50% is considered a partial response (PR). Progression (PD) 
defines as an increase of at least 25% in measurable monoclonal immunoglobulin in 
serum or urine or a rise of ≥25% in urinary light chains. If CR lasts in less than three 
months, it defines progress (PD) (Durie BG, 2006). Overall survival (OS) describes the 
duration from the date of transplantation to death or the latest follow-up date for the 
survivors. Progression free survival (PFS) defines as the duration from the date of 
transplantation to the progress in disease, death, or date of the latest follow-up for 
progression-free patients, whichever occurred first. Transplant-related mortality (TRM) 
was the cumulative death in the first 100 days after allogeneic stem cell transplantation 
without any evidence of disease progression.  
All statistical analyses conducted using SPSS V21.0 (SPSS Inc., Chicago, IL) 
software. Descriptive statistics were applied to summarize the data. The categorical 
data report as rates, and numeric data report as medians and average ± standard 
deviations. The Kruskal Wallis Test was used to analyze engraftment times between 
the groups. Kaplan Meier test uses to analyze PFS and OS, and the log-rank test 
applied for the survival impacting factors. 
  
RESULTS AND DISCUSSION 
 Sixty-three MM patients included who underwent ASCT at the age of 60 or older 
at our center. The patients’ clinical and demographic features give in Table 1. 46 
patients consisting of 24 females and 22 males included in the 60-64-year-old group. 
The 65-69-year-old group included five female and eight male patients, a total of 13 
patients. There were four patients in ≥the 70-year-old group. Pre-transplant disease 
status evaluated that 36% were in CR, 28% were VGPR, 30% were PR, and 4% were 
in stable and progressive disease. Disease status three months after ASCT were 73% 
CR, 4.8% VGPR, 14.2% PR, and 1.5% progressive disease. We could not obtain the 
response evaluation results in 6.5% of the patients from the data. 24 (38%) patients 
received one line, 31 (49%) patients received 2 line chemotherapy, and eight patients 
(6%) received 3 line chemotherapy before ASCT. The dose of conditioning 
chemotherapy for ASCT decided for the age and creatinin, and 12 (19%) patients 
received 140 mg/m2 melphalan, and 51 (81%) patients received 200 mg/m2 
melphalan. 
 Median PFS was 15.5±2.6 months, and the median OS was 28.15±5 months. 
According to age groups, median PFS was 12±2.3 months in the 60-64 age group, 
18.4±6 months in the 65-69 age group, and 26±15 months in the ≥70 age group. 
Median OS was 26.5±6.1 months in the 60-64 age group, 39.66±8.9 months in the 65-
69 age group, and 18 months in the ≥70 age group (Table 2). The survival rates dinot 
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differ according to the age groups (p:0.463 for PFS; p:0.62 for OS ). TRM observes in 
only 1 case (at the age of 64). 
 Median neutrophil engraftment duration was 11 days in 60-64 and 65-69 age 
groups and 12 days in ≥70 age group. Median thrombocyte engraftment duration was 
12 days in 60-64 and 65-69 age groups and 11 days in ≥70 age group. The period of 
both neutrophil and thrombocyte engraftment did not differ according to the age 
groups. In the univariant and multivariant analysis, the relationship between OS, PFS, 
and gender, age groups, MM subgroups, disease stages, the number of therapy lines 
received, radiotherapy, the dose of conditioning regimen they received, the quantity of 
infused CD34+ stem cells, the disease status before and after transplantation give in 
Table 3.  
 42 of 63 patients mobilize with 10 μg/kg subcutaneous granulocyte-colony 
stimulating factor (G-CSF) in 2 divided doses (2×5 mcg/kg). Seven patients had a 
mobilization failure with G-CSF alone; they mobilized with high dose 
cyclophosphamide (4.000 mg/m2) plus G-CSF afterward. One patient could not 
mobilize with a high dose of cyclophosphamide (4.000 mg / m2) plus G-CSF. In this 
patient, mobilization performed using plerixafor plus G-CSF. The mobilization method 
of 13 patients could not reach from the records.  
 
Table 1. Patients’ the clinic and demografic characteristics 
 
Patients’ N (number) 
Age (median) 60 (60-81) 









































The quantity of infused CD34+ 
Stem Cells (median) 
4.45 x106 /kg 
(2,57-8,1) 
Abbreviations: M:multiple myeloma, ISS: International Staging System, 
DS: Durie Salmon, GFR: glomerular filtration rate, min:minute 
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Table 2: Progression-Free-Survival and Overall Survival between Age Groups 
*Kaplan Meier test was used to analyze PFS and OS and p value using SPSS V21.0  
 
Table 3: Factors Impacting Progression-Free-Survival and Overall Survival 
 






The quantity of infused median CD34+ 
Stem Cells 
p: 0.05* p<0.001** 
ISS p: 0,716 p: 0.041* 
Gender p: 0,304 p: 0,810 
Age Groups p: 0,463 p: 0,620 
MM subgroup p: 0,587 p: 0,984 
Melphalan dose  
(140 mg/m2 vs 200 mg/m2) 
p: 0,115 p: 0,578 
Number of chemotherapy lines  p: 0,434 p: 0,272 
Radiotherapy   p: 0,224 p: 0,501 
Pre-transplant disease status p: 0,767 p: 0,054 
Post-transplant disease status p: 0,268 p: 0,811 
Abbreviations:ISS: International Staging System, MM: multiple myeloma,  
a: the log-rank test was applied for the survival impacting factors p value using SPSS 
V21.0. *p value <0.05 ; ** p value <0.001 
 
 A significant relationship between the quantity of infused CD34+ stem cells and 
PFS and OS (p:0.05 and p<0.001, respectively); the amount of infused CD34+ stem 
cells affects OS mostly. While we did not find any relationship between the ISS stage 
and PFS, we found a statistically significant relationship between the ISS stage and 
OS (p:0.041).  
 Over the last two decades, very significant advances in the treatment of MM 
have developed. With the improvement of supportive care, the rate of MM patients 
receiving ASCT over the age of 70 increased to 25% in 2004-2005 that it was 6% in 
1994-1995 (McCarthy PL, 2013). The mobilization of hematopoietic stem cells is 
inadequate for elderly patients, and a higher number of apheresis procedures are 
required (Morris CL, 2003; Micallef IN, 2013). However, an adequate amount of 
hematopoietic stem cells can collect in most elderly patients using plerixafor or high 
dose cyclophosphamide in mobilization (Morris CL, 2003; Micallef IN, 2013). In our 
study, we observed that only one patient had mobilization failure.  Unlike other studies, 
we showed that the quantity of infused median CD34 + stem cells was an essential 
factor affecting survival in the elderly patient group in our study. Patients with better 
bone marrow reserves and adequate stem cell mobilization can prolong survival 
regardless of age. Our recent study has reported that low mobilizer myeloma patients 
have poor overall survival (Yiğenoğlu TN, 2020). Consequently, mobilization dynamics 
Survival  60-64 years 65-69 years ≥70 years p value* 
Progression-free 
Survival  (months) 
12±2,3 18,4±6 26±15 0,463 
Overall Survival 
(months) 
26,5±6,1 39,6±8,9 18 0,620 
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are also important factors affecting the survival of eligible elderly myeloma patients. 
Since there are no prospective trials and optimal melphalan doses for ASCT in the 
elderly MM group, a dose reduction strategy seems reasonable for melphalan over 70 
years of age, so our study supports this data.  
 Age is not the only criterion for ASCT; thus, comorbidities and toxicities also 
essential issues. Evaluating performance status, liver, renal, pulmonary functions, 
history of infection, psychosocial support, patients preferences are the most important 
criteria for considering ASCT in elderly patients. Before developing a treatment plan 
for elderly patients, a comprehensive geriatric evaluation should perform on these 
patients(McCarthy PL, 2013). 
 In the majority of the studies conducted with the elderly populations, melphalan 
administered in lower doses. Some studies on ASCT consolidation in elderly MM 
patients (Gay F,2013; Straka C,2012; Kumar SK, 2013). In the survey conducted by 
Gay et al., in patients between 65 and 75 years old, induction with four courses of 
bortezomib, liposomal doxorubicin, and dexamethasone, followed by tandem ASCT 
(conditioning dose is 100 mg/m2 melphalan for each) and consolidation therapy with 
four courses of lenalidomide and dexamethasone; then maintenance performed with 
lenalidomide alone, the median PFS found 48 months and 5-year OS was 63% (Gay 
F,2013). In previous studies, TRM found in 19% of MM patients over 70 years of age 
and 4% in patients under 70 years of age (Gay F,2013; Straka C,2012; Kumar SK, 
2013). In the study conducted by Stettler et al., while single-day 200 mg/m2 melphalan 
was given to patients under the age of 70 as a conditioning regimen, 140 mg/m2 
melphalan give to the patients over 70, and no TRM was observed (Palumbo A, 1999; 
Stettler J, 2016).  The study conducted by Palumbo et al., it found that TRM was 19% 
in the patients with 200 mg/m2 melphalan group, whereas it was 0% at the dose of 100 
mg/m2 melphalan, and 2% at the amount of 140 mg/m2 melphalan (Palumbo A, 1999).  
On the other hand, in our study, all the patients over 70 were given 140 mg/m2 
melphalan as a conditioning regimen. We did not find any difference between MM 
patients for PFS, OS, and TRM, patients in the 60-69 age group give melphalan 140 
mg / m2, and patients give 200 mg / m2. This finding supports the fact that melphalan 
dose reduction in conditioning regimen is not required in the physically fit patients at 
the ages of 60-69 with no renal failure and comorbidity. Similarly, ASCT with 200 
mg/m2 perform on the MM patients at the ages of 60-69, and no TRM report in the 
study conduct by Stettler et al. (Stettler J, 2016).  
           When the Center for International Blood and Marrow Transplant Research 
(CIBMTR) analyzed 11430 MM patients that performed ASCT between 2008 and 
2011, they found that 3-year PFS and OS were 42% and 78% respectively in patients 
of the 18-59-age group, 38% and 75% in patients of the 60-69-age group, and 33% 
and 72% respectively in patients of ≥ 70 years group. In their study, the older the age 
contained, the lower the survival rate (Sharma M, 2014). Transplant-related mortality 
in our study is consistent with the literature. However, because of the retrospective 
design of our study after an eight-year follow-up between 2010 and 2018, we were 
unable to assess the transplant-related toxicity in detail from the data and did not use 
any fragility scorings for elderly patients. We evaluated patients' eligibility for 
transplantation based on performance scores and organ dysfunction. The developing 
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CONCLUSION 
 In conclusion, our study indicated a high dose (200 mg/m2) melphalan could be 
safely used in physically fit patients between the ages of 60-69. A reduced dose (140 
mg/m2) would be the appropriate dose for the patients over 70. The quantity of infused 
CD34+ stem cells affects elderly MM patients; mobilization dynamics are also 
important for elderly myeloma. Age itself should not consider a barrier to ASCT, and 
a comprehensive geriatric evaluation should perform on older MM patients.  
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